🟡Relating to health benefit plan coverage for chimeric antigen receptor T-cell therapy.

HB 3057

🟡 HB 3057: Access to CAR T-cell Therapy for Insured Texans

What it says it does:
HB 3057 requires most private health insurance plans to cover CAR T-cell therapy when it is medically necessary and administered at an FDA-certified facility in the plan’s network. It is designed to expand access to this advanced cancer treatment.

What it actually changes:
Coverage is limited to in-network facilities. Medicaid and CHIP are excluded. Insurers retain discretion through network control and medical necessity determinations. The final version removed language from the introduced bill that would have forced coverage for any FDA-qualified provider statewide.

Who is pushing for it:
Bristol Myers Squibb, Texas Hospital Association, Texas Healthcare & Bioscience Institute, OneOncology, HB Strategies. The Texas Association of Health Plans registered “on” the bill.

Who benefits:
Pharmaceutical companies manufacturing CAR T therapy, hospitals and oncology networks already in insurer networks, and lobby groups representing healthcare and biotech interests. Insurers benefit by keeping control over which facilities are covered.

Who gets left out or exposed:
Low-income Texans on Medicaid or CHIP, patients in rural areas without in-network CAR T centers, and hospitals or clinics that are FDA-certified but not in-network. Patients are also subject to insurer medical necessity reviews without additional appeals protections.

Why this matters long term:
The bill sets a precedent for coverage mandates tied to insurer networks rather than broad patient choice. Future advanced therapies may follow this model. Costs are shifted to private premiums, which may burden employers and employees, particularly in small businesses.

What to watch next:
Monitor network adequacy for CAR T facilities, access disparities for Medicaid/CHIP patients, insurer denial patterns, and any attempts in future sessions to expand coverage or mandate reporting on approvals and denials.

Bottom line:
HB 3057 expands CAR T coverage in theory, but access depends on insurer networks. Many patients remain excluded, costs shift to private premiums, and the law establishes a model that benefits pharma, hospitals, and insurers while leaving gaps for vulnerable Texans.

#HB3057 #TexasPolicy #CancerTreatment #HealthCoverage #WatchTheRules